{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:53:10Z","timestamp":1787590390385,"version":"build-2736575974"},"reference-count":89,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The complement system includes soluble and cell surface proteins and is an important arm of the innate immune system. Once activated, the complement system rapidly generates proteins with inflammatory and vasoactive activities. Although complement is crucial to host defense and homeostasis, its inappropriate or uncontrolled activation can also drive tissue injury. Glomerulopathy encompasses a spectrum of diseases with diverse etiologies, clinical presentations, and outcomes. Among the intricate web of factors contributing to glomerulopathies pathogenesis, the role of complement activation has emerged as a focal point of research interest and therapeutic intervention. The pioneer drug was eculizumab, which made it possible to drastically change the prognosis of atypical hemolytic uremic syndrome, an otherwise fatal disease. This comprehensive review aims to elucidate the multifaceted interplay between complement pathways and glomerulopathies, shedding light on potential pathways for targeted therapies and improved patient care.<\/jats:p>","DOI":"10.3390\/jcm14030702","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:55:32Z","timestamp":1737532532000},"page":"702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Micaela","family":"Gentile","sequence":"first","affiliation":[{"name":"UO Nefrologia, Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-2142","authenticated-orcid":false,"given":"Lucio","family":"Manenti","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Azienda Sociosanitaria Liguria 5, 19121 La Spezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules Great and Small: The Complement System","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.ackd.2019.10.003","article-title":"Complement and the Kidney: An Overview","volume":"27","author":"Thurman","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Anwar, I.J., DeLaura, I., Ladowski, J., Gao, Q., Knechtle, S.J., and Kwun, J. (2022). Complement-targeted therapies in kidney transplantation\u2014Insights from preclinical studies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.984090"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.atherosclerosis.2018.01.021","article-title":"Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?","volume":"269","author":"Polanco","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1538-7836.2010.04172.x","article-title":"Complement in atherosclerosis: Friend or foe?","volume":"9","author":"Speidl","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8563845","DOI":"10.1155\/2019\/8563845","article-title":"Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation","volume":"2019","author":"Marchio","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semnephrol.2017.05.018","article-title":"Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement","volume":"37","author":"Noris","year":"2017","journal-title":"Semin. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.13150","article-title":"The complement alternative pathway and hemostasis","volume":"313","author":"Noris","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.15252\/embj.201591881","article-title":"Complement activation, regulation, and molecular basis for complement-related diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The Amplification Loop of the Complement Pathways","volume":"Volume 104","author":"Lachmann","year":"2009","journal-title":"Advances in Immunology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","article-title":"Role of C5a in Inflammatory Responses","volume":"23","author":"Guo","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.4049\/jimmunol.169.9.4702","article-title":"Cutting Edge: Localization of the Host Recognition Functions of Complement Factor H at the Carboxyl-Terminal: Implications for Hemolytic Uremic Syndrome","volume":"169","author":"Pangburn","year":"2002","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"152707","DOI":"10.1016\/j.imbio.2023.152707","article-title":"Complement and coagulation crosstalk\u2014Factor H in the spotlight","volume":"228","author":"Heurich","year":"2023","journal-title":"Immunobiology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Van Den Bos, R.M., Pearce, N.M., Granneman, J., Brondijk, T.H.C., and Gros, P. (2019). Insights into Enhanced Complement Activation by Structures of Properdin and Its Complex with the C-Terminal Domain of C3b. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02097"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.kint.2022.07.035","article-title":"Factor H related proteins modulate complement activation on kidney cells","volume":"102","author":"Renner","year":"2022","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Goodfellow, R.X., Ghiringhelli Borsa, N., Dunlop, H.C., Presti, S.A., Meyer, N.C., Shao, D., Roberts, S.M., Jones, M.B., and Pitcher, G.R. (2022). Complement Factor I Variants in Complement-Mediated Renal Diseases. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.866330"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pedersen, D.V., Gadeberg, T.A.F., Thomas, C., Wang, Y., Joram, N., Jensen, R.K., Mazarakis, S.M.M., Revel, M., El Sissy, C., and Petersen, S.V. (2019). Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02007"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hardy, M.P., Mansour, M., Rowe, T., and Wymann, S. (2023). The Molecular Mechanisms of Complement Receptor 1-It Is Complicated. Biomolecules, 13.","DOI":"10.3390\/biom13101522"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e20191699","DOI":"10.1084\/jem.20191699","article-title":"Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis","volume":"217","author":"Angeletti","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-immunol-042617-053245","article-title":"Complement and the Regulation of T Cell Responses","volume":"36","author":"West","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal Thrombotic Microangiopathy: A Review","volume":"81","author":"Genest","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of Thrombotic Microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic Microangiopathy and the Kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"ref_28","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (2024, November 18). Genetic Atypical Hemolytic-Uremic Syndrome, GeneReviews\u00ae, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1367\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.revmed.2009.09.039","article-title":"Syndrome h\u00e9molytique et ur\u00e9mique li\u00e9 \u00e0 des anomalies du compl\u00e9ment","volume":"32","author":"Fakhouri","year":"2011","journal-title":"La Rev. M\u00e9decine Interne"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic\u2013Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights From the Use in Clinical Practice of Eculizumab in Adult Patients with Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cordero, L., Cavero, T., Guti\u00e9rrez, E., Trujillo, H., Sandino, J., Au\u00f1\u00f3n, P., Rivero, M., and Morales, E. (2024). Rational use of eculizumab in secondary atypical hemolytic uremic syndrome. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1310469"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: Recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Liu, X., Zhang, J., and Zhang, B. (2024). Real-world safety profile of eculizumab: An analysis of FDA adverse event reporting system and systematic review of case reports. Expert Opin. Drug Saf., 1\u20137.","DOI":"10.1080\/14740338.2024.2392885"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/ndt\/gfad182","article-title":"C3G and Ig-MPGN-treatment standard","volume":"39","author":"Noris","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative Glomerulonephritis\u2014A New Look at an Old Entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014Understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ki.2011.399","article-title":"Membranoproliferative glomerulonephritis and C3 glomerulopathy: Resolving the confusion","volume":"81","author":"Sethi","year":"2012","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative Complement Pathway Inhibition with Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ekir.2022.01.124","article-title":"POS-112 Effect of Avacopan, a Selective C5A receptor Inhibitor, on Complement 3 Glomerulopathy Histologic Index of Disease Chronicity","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bomback, A.S., Herlitz, L.C., Kedia, P.P., Petersen, J., Yue, H., and Lafayette, R.A. (2024). Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial. J. Am. Soc. Nephrol., 10-1681.","DOI":"10.1681\/ASN.0000000526"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ayano, M., and Horiuchi, T. (2023). Complement as a Biomarker for Systemic Lupus Erythematosus. Biomolecules, 13.","DOI":"10.3390\/biom13020367"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/j.ekir.2022.09.012","article-title":"Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis","volume":"7","author":"Rossi","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wright, R.D., Bannerman, F., Beresford, M.W., and Oni, L. (2020). A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-01888-5"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.xkme.2023.100688","article-title":"Novel Therapeutics for Management of Lupus Nephritis: What Is Next?","volume":"5","author":"Thakare","year":"2023","journal-title":"Kidney Med."},{"key":"ref_53","first-page":"939","article-title":"IgA glomerular deposits in renal disease","volume":"1","author":"Berger","year":"1969","journal-title":"Transpl. Proc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA Nephropathy: An Interesting Autoimmune Kidney Disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA Nephropathy: Core Curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Cook","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rossi, G.M., Ricco, F., Pisani, I., Delsante, M., Maggiore, U., Fiaccadori, E., and Manenti, L. (2024). C3 Hypocomplementemia Predicts the Progression of CKD Towards End-Stage Kidney Disease in IgA Nephropathy, Irrespective of Histological Evidence of Thrombotic Microangiopathy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092594"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA Nephropathy Is Associated with Low Circulating Mannan-Binding Lectin\u2013Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H\u2013Related Protein-5 (FHR5) Deposition","volume":"3","author":"Troldborg","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ckj\/sfad025","article-title":"Immune abnormalities in IgA nephropathy","volume":"16","author":"Gentile","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Perkovic, V., Barratt, J., Rovin, B., Kashihara, N., Maes, B., Zhang, H., Trimarchi, H., Kollins, D., Papachristofi, O., and Jacinto-Sanders, S. (2024). Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N. Engl. J. Med., NEJMoa2410316.","DOI":"10.1056\/NEJMoa2410316"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Barratt, J., Lafayette, R.A., and Floege, J. (2024). Therapy of IgA nephropathy: Time for a paradigm change. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1461879"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014An open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-Associated Vasculitis: Core Curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis\u2014Clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/BOR.0000000000000914","article-title":"The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: Pathogenic player and therapeutic target","volume":"35","author":"Mazzariol","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative Complement Pathway in the Pathogenesis of Disease Mediated by Anti-Neutrophil Cytoplasmic Autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00467-016-3475-5","article-title":"Pathogenesis and treatment of ANCA-associated vasculitis\u2014A role for complement","volume":"33","author":"Noone","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molimm.2020.10.015","article-title":"Complement-mediated kidney diseases","volume":"128","author":"Poppelaars","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0272-6386(95)90663-0","article-title":"Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis and thrombotic microangiopathy","volume":"26","author":"Hirsch","year":"1995","journal-title":"Am. J. Kidney Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2215\/CJN.07910814","article-title":"Clinicopathologic Characteristics and Outcomes of Renal Thrombotic Microangiopathy in Anti-Neutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis","volume":"10","author":"Chen","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes Among Patients with ANCA-Associated Renal Vasculitis","volume":"10","author":"Manenti","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11739-017-1636-6","article-title":"Complement blockade in ANCA-associated vasculitis: An index case, current concepts and future perspectives","volume":"12","author":"Manenti","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ekir.2019.11.021","article-title":"Treatment of Aggressive Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis with Eculizumab","volume":"5","author":"Huizenga","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bekker, P., Dairaghi, D., Seitz, L., Leleti, M., Wang, Y., Ertl, L., Baumgart, T., Shugarts, S., Lohr, L., and Dang, T. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164646"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive Treatment with Avacopan, an Oral C5a Receptor Inhibitor, in Patients with Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_85","first-page":"229","article-title":"Membranous nephropathy","volume":"45","author":"Dantas","year":"2023","journal-title":"Braz. J. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00281-007-0091-2","article-title":"Target antigens and nephritogenic antibodies in membranous nephropathy: Of rats and men","volume":"29","author":"Ronco","year":"2007","journal-title":"Semin. Immunopathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1681\/ASN.2005010096","article-title":"Contrasting Roles of Complement Activation and Its Regulation in Membranous Nephropathy","volume":"16","author":"Cunningham","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Chung, E.Y.M., Wang, Y.M., Keung, K., Hu, M., McCarthy, H., Wong, G., Kairaitis, L., Bose, B., Harris, D.C.H., and Alexander, S.I. (2022). Membranous nephropathy: Clearer pathology and mechanisms identify potential strategies for treatment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1036249"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:33:39Z","timestamp":1759919619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14030702"],"URL":"https:\/\/doi.org\/10.3390\/jcm14030702","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}